Regulation of microglia - potential new drug targets in the CNS

Expert Opinion on Therapeutic Targets

Volumn 5, Issue 6, 2001, Pages 655-668

  Aldskogius, Håkan ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Antigen presenting cell; Astrocytes; Complement; Cytokines; Eicosanoids; Free radicals; Growth factors; Inflammation; Macrophage; Neurodegeneration; Neurotrauma; Pain; Phagocytosis; Stroke

Indexed keywords

EID: 26844528859     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.5.6.655     Document Type: Review

References (207)

1. LING EA, WONG WC: The origin and nature of ramified and amoeboid microglia: a historical review and current concepts. Glia (1993) 7(1):9-18.
2. CUADROS MA, NAVASCUÉS J: The origin and differentiation of microglial cells duringdevelopment. Prog. Neurobiol. (1998) 56(2):173-189.
3. REZAIE P, MALE D: Colonisation of the developing human brain and spinal cord by microglia: a review. Microsc. Res. Tech. (1999) 45(6):359-382.
4. MENTLEIN R, SIEVERS J: Astroglial-microglial interactions. In: Glial Interfaces inthe Nervous System- Role in Repair and Plasticity. Aldskogius H, Fraher J (Eds.), IOS Press, Amsterdam (2001). In press.
5. WILMS H, WOLLMER MA, SIEVERS J: In vitro-staining specificity of the antibody 5-D-4 for microglia but not for monocytes and macrophages indicates that microglia are a unique subgroup of the myelomonocytic lineage. J. Neuroimmunol. (1999) 98(2):89-95.
6. FLARIS NA, DENSMORE TL, MOLLESTON MC et al.: Characterization of microglia and macrophages in the central nervous system of rats: definition of the differential expression of molecules using standard and novel monoclonal antibodies in normal CNS and in four models of parenchymal reaction. Glia (1993) 7(1):34-40.
7. STREIT WJ, GRAEBER MB: Heterogeneity of microglial and perivascular cell populations: insights from the facial nucleus paradigm. Glia (1993) 7(1):68-74.
8. HICKEY WF, KIMURA H: Perivascular microglial cells of the CNS are bone marrow derived and present antigen in vivo. Science (1988) 239(4837):290-292.
9. ANGELOV DN, WALTHER M, STREPPEL M et al.: The cerebral perivascular cells. Adv. Anat. Embryol. Cell Biol. (1998) 147:1-87.
10. REN L, LUBRICH B, BIBER K et al.: Differential expression of inflammatory mediators in rat microglia cultured from different brain regions. Mol. Brain Res. (1999) 65(2):198-205.
11. MITTELBRONN M, DIETZ K, SCHLUESSENER HJ et al.: Local distribution of microglia in the normal adult human central nervous system differs by up to one order of magnitude. Acta Neuropathol. (Berl.) (2001) 101(3):249-255.
12. SHENG JG, MRAK RE, GRIFFIN WS: Enlarged and phagocytic, but not primed, interleukin-a alphaimmunoreactive microglia increase with age in normal human brain. Acta Neuropathol. (Berl.) (1998) 95(3):229-234.
13. KREUTZBERG GW: Microglia - a sensor of pathological events in the CNS. Trends Neurosci. (1996) 19(8):312-318.
14. RAIVICH G, BOHATSCHEK M, KLOSS CU et al.: Neuroglial activation repertoire in the injured brain: graded response, molecular mechanisms and cues to physiological function. Brain Res. Rev. (1999) 30(1):77-105.
15. STREIT WJ, WALTHER SA, PENNELL NA: Reactive microgliosis. Prog. Neurobiol. (1999) 57(6):563-581.
16. STREIT WJ, GRAEBER MB: Microglia: a pictorial. Prog. Histochem. Cytochem. (1996) 31(1):1-89.
17. ALDSKOGIUS H, KOZLOVA EN: Central neuron-glial and glial-glial interactions following axon injury. Prog. Neurobiol. (1998) 55(1):1-26.
18. GONZÁLEZ-SCARANO F, BALTUCH G: Microglia as mediators of inflammatory and degenerative diseases. Annu. Rev. Neurosci. (1999) 22:219-240.
19. STOLL G, JANDER S: The role of microglia and macrophages in the pathophysiology of the CNS. Prog. Neurobiol. (1999) 58(3):233-247.
20. GEBICKE-HAERTER PJ: Microglia in neurodegeneration: molecular aspects. Micr. Res. Tech.(2001) 54(1):47-58.
21. GIULIAN D, HAVERKAMP LJ, YU J et al.: The HHQK domain of beta-amyloid provides a structural basis for the immunopathology of Alzheimer's disease. J. Biol. Chem. (1998) 273(45):29719-29726.
22. MCGEER PL, MCGEER EG: The importance of inflammatory mechanisms in Alzheimer disease. Exp. Gerontol. (1998) 33(5):371-378.
23. MCGGER PL, MCGEER EG: Brain inflammation in Alzheimer disease and therapeutic implications. Curr. Pharm. Des. (1999) 5(10):821-836.
24. SCHUBERT P, OGATA T, MIYAZAKI H et al.: Pathological immuno-reactions of glial cells in Alzheimer's disease and possible sites of interference. J. Neural Transm. (1998) Suppl. 54:167-174.
25. COMBS CK, JOHNSON DE, CANNADY SB et al.: Identification of microglial signal transduction pathways mediating a neurotoxic response to amyloidogenic fragments of β-amyloid and prion proteins. J. Neurosci. (1999) 19(3):928-939.
26. KALARIA RN: Microglia and Alzheimer's disease. Curr. Opin. Hematol. (1999) 6:15-24.
27. AKIYAMA H, BARGER S, BARNUM S et al.: Inflammation and Alzheimer's disease. Neurobiol. Aging (2000) 21(3):383-421.
28. EIKELENBOOM P, ROZEMULLER AJ, HOOZEMANS JJ et al.: Neuroinflammation and Alzheimer disease: clinical and therapeutic implications. Alzheimer Dis. Assoc. Disord. (2000) Suppl. 1:S54-S61.
29. SMITS HA, BOVEN LA, PEREIRA CF et al.: Role of macrophage activation in the pathogenesis of Alzheimer's disease and human immunodeficiency virus type 1-associated dementia. Eur. J. Clin. Invest. (2000) 30(6):526-535.
30. COMBS CK, KARLO JC, KAO SC et al.: Beta-amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J. Neurosci. (2001) 21(4):1179-1188.
31. MATSUOKA Y, PICCIANO M, MALESTER B et al.: Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimers disease. Am. J. Pathol. (2001) 158(4):1345-1354.
32. SZCZEPANIK AM, RAMPE D, RINGHEIM GE: Amyloid-beta peptide fragments p3 and p4 induce proinflammatory cytokine and chemokine production in vitro and in vivo. J. Neurochem. (2001) 77(1):304-317.
33. GIULIAN D, YU J, TOM D et al.: Study of receptor-mediated neurotoxins released by HIV-1-infected mononuclear phagocytes found in human brain. J. Neurosci. (1996) 16(10):3139-3153.
34. GLASS JD, JOHNSON RT: Human immunodeficiency virus and the brain. Annu. Rev. Neurosci. (1996) 19:1-26.
35. LIPTON SA: Neuronal injury associated with HIV-1: approaches to treatment. Annu. Rev. Pharmacol. Toxicol. (1998) 38:159-177.
36. KAUL M, GARDEN GA, LIPTON SA: Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature (2001) 410(6831):988-994.
37. MOLLACE V, NOTTET HSLM, CLAYETTE P et al.: Oxidative stress and neuroAIDS: triggers, modulators and novel antioxidants. Trends Neurosci. (2001) 24(7):411-416.
38. GIESE A, BROWN DR, GROSCHUP MH et al.: Role of microglia in neuronal cell death in prion disease. Brain Pathol. (1998) 8(3):449-457
39. V EITZEN U, EGENSPERGER R, KOSEL S et al.: Microglia and the development of spongiform change in Creutzfeldt-Jakob disease. J. Neuropathol. Exp. Neurol. (1998) 57(3):246-256.
40. PEYRIN JM, LASMEZAS CI, HAIK S et al.: Microglial cells respond to amyloidogenic PrP peptide by the production of inflammatory cytokines. Neuroreport (1999) 10(4):723-729.
41. REZALE P, IANTOS PL: Microglia and the pathogenesis of spongiform encephalopathies. Brain Res. Rev. (2001) 35(1):55-72.
42. YUAN L, NEUFELD AH: Tumor necrosis factor-α: a potentially neurodestructive cytokine produced by glia in the human glaucomatous optic nerve head. Glia (2000) 32(1):42-50.
43. YUAN L, NEUFELD AH: Activated microglia in the human glaucomatous optic nerve head. J. Neurosci. Res. (2001) 64(5):523-532.
44. DE KOZAK Y, COTINET A, GOUREAU O et al.: Tumor necrosis factor and nitric oxide production by resident retinal glial cells from rats presenting hereditary retinal degeneration. Ocul. Immunol. Inflamm. (1997) 5(2):85-94.
45. PENFOLD PL, MADIGAN MC, GILLIES MC et al.: Immunological and aetiological aspects of macular degeneration. Prog. Retin. Eye Res. (2001) 20(3):385-414.
46. ROQUE RS, ROSALES AA, JINGJING L et al.: Retina-derived microglial cells induce photoreceptor cell death in vitro. Brain Res. (1999) 836 (81-82):110-119.
47. TRAPP BD, BO L, MORK S et al.: Pathogenesis of tissue injury in MS lesions. J. Neuroimmunol. (1999) 98(1):49-56.
48. JUEDES AE, RUDDLE NH: Resident and infiltrating central nervous system apcs regulate the emergence and resolution of experimental autoimmune encephalomyelitis. J. Immunol. (2001) 166(8):5168-5175.
49. WINDERCHUK DM, LUCCHINETTI CF, NOSEWORTHY JH: Multiple sclerosis: current pathophysiological concepts. Lab. Invest. (2001) 81(3):263-281.
50. SMITH ME: Phagocytosis of myelin in demyelinative disease: a review. Neurochem. Res. (1999) 24(2):261-268.
51. PERRY VH, ANTHONY DC: Axon damage and repair in multiple sclerosis. Phil. Trans. R. Soc. Lond. (1999) 354(1390):1641-1647.
52. GIULIAN D, CORPUZ M, CHAPMAN S et al.: Reactive mononuclear phagocytes release neurotoxins after ischemic and traumatic injury to the central nervous system. J. Neurosci. Res. (1993) 36(6):681-693.
53. GIULIAN D, VACA K: Inflammatory glia mediate delayed neuronal damage after ischemia in the central nervous system. Stroke (1993) 24(Suppl. 12):184-190.
54. WOOD PL: Microglia as a unique cellular target in the treatment of stroke: potential neurotoxic mediators produced by activated microglia. Neurol. Res. (1995) 17(4):242-248.
55. STOLL G, JANDER S, SCHROETER M: Inflammation and glial responses in ischemic brain lesions. Prog. Neurobiol. (1998) 56(2):149-171.
56. FITCH MT, DOLLER C, COMBS CK et al.: Cellular and molecular mechanisms of glial scarring and progressive cavitation: In vivo and in vitro analysis of inflammation-induced secondary injury after CNS trauma. J. Neurosci. (1999) 19(19):8182-8198.
57. GREGERSEN R, LAMBERTSEN K, FINSEN B: Microglia and macrophages are the major source of tumor necrosis factor in permanent middle cerebral artery occlusion in mice. J. Cereb. Blood Flow Metab. (2000) 20(1):53-65.
58. MABUCHI T, KITAGAWA K, OHTSUKI T et al.: Contribution of microglia/ macrophage to expansion of infarction and response of oligodendrocytes after focal cerebral ischemia in rats. Stroke (2000) 31(7):1735-1743.
59. KATO H, WALZ W: The initiation of the microglial response. Brain Pathol. (2000) 10(1):137-143.
60. LU J, MOCHALA S, KAUR C et al.: Cellular inflammatory response associated with breakdown of blood-brain barrier after closed head injury in rats. J. Neurotrauma (2001) 18(4):399-408.
61. PRICE DL, WONG PC, BORCHELT DR et al.: Amyotrophic lateral sclerosis and Alzheimer's disease. Lessons from model systems. Rev. Neurol. (Paris) (1997) 153(8-9):484-495.
62. HALL ED, OOSTVEEN JA, GURNEY ME: Relationship of microglial and astrocytic activation in disease onset and progression in a transgenic model of familial ALS. Glia (1998) 23(3): 249-256.
63. BOILLÉE S, VIALA L, PESCHANSKI M et al.: Differential microglial response to progressive neurodegeneration in the murine mutant Wobbler. Glia (2001) 33(4):277-287.
64. SINGHRAO SK, NEAL JW, MORGAN BP et al.: Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease. Exp. Neurol. (1999) 159(2):362-376.
65. SAPP E, KEGEL KB, ARONIN N et al.: Early and progressive accumulation of reactive microglia in the Huntington disease brain. J. Neuropathol. Exp. Neurol. (2001) 60(2):161-172.
66. KURKOWSKA-JASTRZEBSKA I, WRONSKA A, KOHUTNICAK M et al.: MHC class II positive microglia and lymphocytic infiltration are present in the substantia nigra and striatum in mouse model of Parkinsons's disease. Acta Neurobiol. Exp. (1999) 59(1):1-8.
67. KNOTT C, STERN G, WILKIN GP: Inflammatory receptors in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol. Cell Neurosci. (2000) 16(6):724-739.
68. WATKINS LR, MARTIN D, ULRICH P et al.: Evidence for the involvement of spinal cord glia in subcutaneous formalin induced hyperalgesia in the rat. Pain (1997) 71(3):225-235.
69. COYLE DE: Partial peripheral nerve injury leads to activation of astroglia and microglia which parallels the development of allodynic behavior. Glia (1998) 23(1):75-83.
70. HASHIZUME H, DELEO JAG, COLBURN RW et al.: Spinal glial activation and cytokine expression after lumbar root injury in the rat. Spine (2000) 25(10):1206-1217.
71. WATKINS LR, MILLIGAN ED, MAIER SF: Glial activation: a driving forvce for pathological pain. Trends Neurosci. 24(8):450-455.
72. DELEO JA, YEZIERSKI RP: The role of neuroinflammation and neuroimmune activation in persistent pain. Pain (2001)90(1-2):1-6.
73. GEHRMANN J, MIES G, BONNEKOH P et al.: Microglial reaction in the rat cerebral cortex induced by cortical spreading depression. Brain Pathol. (1993) 3(1):11-17.
74. JANDER S, SCHROETER M, PETERS O et al.: Cortical spreading depression induces proinflammatory cytokine gene expression in the rat brain. J. Cereb. Blood Flow Metab. (2001) 21(3):218-225.
75. PARSONS AA: Recent advances in mechanisms of spreading depression. Curr. Opin. Neurol. (1998) 11(3):227-231.
76. WELCH KM: Pathogenesis of migraine. Semin. Neurol. (1997) 17(4):335-341.
77. ZIMMER LA, ENNIS M, SHIPLEY MT: Soman-induced seizures rapidly activate astrocytes and microglia in discrete brain regions. J. Comp. Neurol. (1997) 378(4):482-492.
78. JANKOWSKY JL, PATTERSON PH: The role of cytokines and growth factors in seizures and their sequelae. Prog. Neurobiol. (2001) 63(2):125-149.
79. KEMPER TL, BLATT GJ, KILLIANY RJ et al.: Neuropathology of progressive cognitive decline in chronically hypertensive rhesus monkeys. Acta Neuropathol. (Berl.) (2001) 101(2):145-153.
80. BEZZI P, DOMERCQ M, BRAMBILLA L et al.: CXCR4-activated astrocyte glutamate release via TNF-α: amplification by microglia triggers neurotoxicity. Nature Neurosci. (2001) 4(7):702-710.
81. HEMMER K, FRANSEN L, VANDERSTICHELE H et al.: An in vitro model for the study of microglia-induced neurodegeneration: involvement of nitric oxide and tumor necrosis factor-alpha. Neurochem. Int. (2001) 38(7):557-565.
82. CHAO CC, HU S, GEKKER G et al.: U50,488 protection against HIV-1-related neurotoxicity: involvement of quionolinic acid suppression. Neuropharmacology (2000) 39(1):150-160.
83. GASQUE P, DEAN YD, MCGREAL EP et al.: Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology (2000) 49(1-2):171-186.
84. SINGHRAO SK, NEAL JW, RUSHMERE NK et al.: Spontaneous classical pathway activation and deficiency of membrane regulators render human neurons susceptible to complement lysis. Am. J. Pathol. (2000) 157(3):905-918.
85. EMMERLING MR, WATSON MD, RABY CA et al.: The role of complement in Alzheimer's disease pathology. Biochim. Biophys. Acta (2000) 1502(1):158-171.
86. MUKHERJEE P, PASINETTI GM: The role of complement anaphylatoxin C5a in neurodegeneration: implications in Alzheimer's disease. J. Neuroimmunol. (2000) 105(2):124-130.
87. HEAD E, AZIZEH BY, LOTT IT et al.: Complement association with neurons and beta-amyloid deposition in the brains of aged individuals with Down syndrome. Neurobiol. Dis. (2001) 8(2):252-265.
88. STAHEL PF, MORGANTI-KOSSMANN MC, KOSSMANN T: The role of the complement system in traumatic brain injury. Brain Res. Rev. (1998) 27(3):243-256.
89. HUA Y, XI GH, KEEP RF et al.: Complement activation in the brain after experimental intracerebral hemorrhage. J. Neurosurg. (2000) 92(6):1016-1022.
90. SCHAFER MK, SCHWAEBLE WJ, POST C et al.: Complement C1q is dramatically up-regulated in brain microglia in response to transient global cerebral ischemia. J. Immunol. (2000) 164(10):5446-5452.
91. O'BARR S, COOPER NR: The C5a complement activation peptide increases IL-1β and 11-6 release from amyloid-β primed human monocytes: implications for Alzheimer's disease. J. Neuroimmunol. (2000) 109(1): 87-94.
92. SORTINO MA, CONDORELLI F, VANCHERI C et al.: Tumor necrosis factor-alpha induces apoptosis in immortalized hypothalamic neurons: involvement of ceramide-generating pathways. Endocrinology (1999) 140(10):4841-4849.
93. DOWNEN M, AMARAL TD, HUA LL et al.: Neuronal death in cytokine-activated primary human brain cell culture: role of tumor necrosis factor-alpha. Glia (1999) 28(2):114-127.
94. MINGHETTI L, POLAZZI E, NICOLINI A et al.: Possible role of microglial prostanoids and free radicals in neuroprotection and neurodegeneration. Adv. Exp. Mid. Biol. (1999) 468:109-119.
95. PASINETTI GM: Cyclooxygenase and inflammation in Alzheimer's disease: experimental approaches and clinical interventions. J. Neurosci. Res. (1998) 54(1):1-6.
96. WALSH CT, PERRY VH, MIGHETTI L Cyclooxygenase-2 is highly expressed in microglial-like cells in murine model of prion disease. Glia (2000) 59(4):392-396.
97. HOOZEMANS JJ, ROZEMULLER AJ, JANSSEN I et al.: Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropathol. (Berl.) (2001) 101(1):2-8.
98. KITAMURA Y, SHIMOHAMA S, KOIKE H et al.: Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer's disease brains. Biochem. Biphys. Res. Comm. (1999) 254(3):582-586.
99. COLTON CA, KERI JE, CHEN WT et al.: Protease production by cultured microglia: substrate gel analysis and immobilized matrix degradation. J. Neurosci. Res. (1993) 35(3):297-304.
100. GOTTSCHALL PE, DEB S: Regulation of matrix metalloproteinase expression in astrocytes, microglia and neurons. Neuroimmunodulation (1996) 3(2-3):69-75.
101. CROSS AK, WOODROOFE MN: Chemokine modulation of matrix metalloproteinases and TIMP production in adult microglia and a human microglial cell line in vitro. Glia (1999) 28(2):183-189.
102. KINGHAM PJ, POCOCK JM: Microglial secreted cathepsin B induces neuronal apoptosis. J. Neurochem. (2001) 76(5):1475-1484.
103. FERRARI D, LOS M, BAUER MK et al.: P2Z purinoreceptor ligation induces activation of caspases with distinct roles in apoptotic and necrotic alterations of cell death. FEBS Lett. (1999) 447(1):71-75.
104. ZHAO ML, KIM MO, MORGELLO S et al.: Expression of inducible nitric oxide synthase, interleukin-1 and caspase-1 in HIV-1 encephalitis. J. Neuroimmunol. (2001) 115(1-2):182-191.
105. PERRY VH: A revised view of the central nervous microenvironment and major histocompatibility complex class II antigen presentation. J. Neuroimmunol. (1998) 90(2):113-121.
106. HALL GL, GIRDLESTONE J, COMPSTON DA et al.: Recall antigen presentation by γ-interferon-activated microglia results in T cell activation and propagation of the immune response. J. Neuroimmunol. 98(2):105-111.
107. FERRARI D, CHIOZZI P, FALZONI S et al.: Purinergic modulation of interleukin-1beta release from microglial cells stimulated with bacterial endotoxin. J. Exp. Med. (1997) 185(3):579-582.
108. 2+ in human microglia. Neuroscience (1999) 91(1):343-352.
109. i/o-couples P2Y receptors. J. Neurosci. (2001) 21(6):1975-1982.
110. FIEBICH BL, BIBER K, LIEB K et al.: Cyclooxygenase-2 expression in rat microglia is induced by adenosine A2a-receptors. Glia (1996) 18(2):152-160.
111. + channel mRNA expression by stimulation of adenosine A2a-receptors in cultured rat microglia. Glia (1999) 25(2):120-130.
112. PYO H, JOE E, JUNG S et al.: Gangliosides activate cultured rat brain microglia. J. Biol. Chem. (1999) 274(49):34583-34589.
113. - channels and their involvement in proliferation of rat microglial cells. Glia (1996) 17(3):225-236.
114. CHATTOPADHYAY N, YE C, YAMAGUCHI T et al.: The extracellular calcium-sensing receptor is expressed in rat microglia and modulates an outward K+ channel. J. Neurochem. (1999) 72(5):1915-1922.
115. CHANG RC, HUDSON PM, WILSON BC et al.: High concentration of extracellular potassium enhance bacterial endotoxin lipopolysaccharide-induced neurotoxicity in glia-neuron mixed cultures. Neuroscience (2000) 97(4):757-764.
116. WALZ W, BEKAR LK: Ion channels in cultured microglia. Micr. Res. Tech. (2001) 54(1):26-33.
117. MURPHY GM, Jr., YANG L, CORDELL B: Macrophage colony-stimulating factor augments beta-amyloid-induced interleukin-1, interleukin-6, and nitric oxide production by microglial cells. J. Biol. Chem. (1998) 273(33):20967-20971.
118. (2+) responses in human microglia. Neurosci. Lett. (2000) 281(2-3):83-86.
119. MACIEJEWSKI-LENOIR D, CHEN S, FENG L et al.: Characterization of fractalkine in rat brain cells: migratory and activation signals for CXCR-1-expressing microglia. J. Immunol. (1999) 163(3):1628-1635.
120. CHAPMAN GA, MOORE K, HARRISON D et al.: Fractalkine cleavage from neuronal membranes represents an acute event in the inflammatory response to excitotoxic brain damage. J. Neurosci. (Online) (2000) 20(15):RC87
121. CROSS AK, WOODROOFE MA: Immunoregulation of microglial functional properties. Micr. Res. Tech. (2001) 54(1)10-17.
122. ILSCHNER S, NOLTE C, KETTENMANN H: Complement factor C5a and epidermal growth factor trigger the activation of outward potassium currents in cultured murine microglia. Neuroscience (1996) 73(4):1109-1120.
123. VIVIANI B, CORSINI E, GALLI CL et al.: Dying neural cells activate glia through the release of a protease product. Glia (2000) 32(1):84-90.
124. KOSKI CL, ESTEP AE, SAWANT-MANE S et al.: Complement regulatory molecules on human myelin and glial cells: differential expression affects the deposition of activated complement proteins. J. Neurochem. (1996) 66(1):303-312.
125. DAVOUST N, NATAF S, HOLERS M et al.: Expression of the murine complement regulatory protein Crry by glial cells and neurons. Glia (1999) 27(2):162-170.
126. MORGAN BP: Regulation of the complement membrane attack pathway. Crit. Rev. Immunol. (1999) 19(3):173-198.
127. SHENG WS, HU S, KRAVITZ FH et al.: Tumor necrosis factor-α upregulates human microglial cell production of interleukin-10 in vitro. Clin. Diag. Lab. Immunol. (1995) 2(5):604-608.
128. SAWADA M, SUZUMURA A, HOSOYA H et at.: Interleukin-10 inhibits both production of cytokines and expression of cytokine receptors in microglia. J. Neurochem. (1999) 72(4):1466-1471.
129. BRODERICK C, DUNCAN L, TAYLOR N et al.: IFN-γ and LPS-mediated IL-10-dependent suppression of retinal microglial activation. Invest. Ophtalmol. Vis. Sci. (2000) 41(9):2613-2622.
130. NISHIBORI M, NAKAYA N, TAHARA A et al.: Presence of macrophage migration inhibitory factor (MIF) in ependyma, astrocytes and neurons in the bovine brain. Neurosci. Lett. (1996) 213(3):193-196.
131. OGATAA, NISHIHIRA J, SUZUKI T et al.: Identification of macrophage migration inhibitory factor mRNA expression in neural cells of the rat brain by in situ hybridization. Neurosci. Lett. (1998) 246(3):173-177.
132. OYAMA R, YAMAMOTO H, TITANI K: Glutamine synthase, hemoglobin alpha-chain, and macrophage migration inhibitory factor binding to amyloid beta-protein: their identification in rat brain by a novel affinity chromatography and in Alzheimer's disease brain by immunoprecipitation. Biochim. Biophys. Acta (2000) 1479(1-2):91-102.
133. HAILER NP, WIRJATIJASA F, ROSER N et al.: Astrocytic factors protect neuronal integrity and reduce microglial activation in an in vitro model of N-methyl-D-aspartate-induced excitotoxic injury in organotypic hippocampal slice cultures. Eur. J. Neurosci. (2001) 14(2):315-326.
134. SMITH ME, HOERNER MT: Astrocytes modulate macrophage phagocytosis of myelin in vitro. J. Neuroimmunol. (2000) 102(2):154-162.
135. CHANG RCC, CHEN W, HUDSON P et al.: Neurons reduce glial responses to lipopolysaccharide (LPS) and prevent injury of microglial cells from over-activation by LPS. J. Neurochem. (2001) 76(4):1042-1049.
136. HAYS SJ: Therapeutic approaches to the treatment of neuroinflammatory disorders. Curr. Pharm. Des. (1998) 4(4):335-348.
137. LUCCA U: Nonsteroidal anti-inflammatory drugs and Alzheimer's disease. CNS Drugs (1999) 11(3):207-224.
138. HULL M, LIEB K, FIEBICH BL: Anti-inflammatory drugs: a hope for Alzheimer's disease? Expert Opin. Invest. Drugs (2000) 9(4):671-683.
139. LIEBESKIND DS, KASNER SE: Neuroprotection for ischaemic stroke. An unattainable goal? CNS Drugs (2001) 15(3):165-174.
140. CAGGIANO AO, KRAIG RP: Prostaglandin E2 and 4-aminopyridine prevent the lipopolysaccharide-induced outwardly rectifying potassium current and interleukin-1β production in cultured rat microglia. J. Neurochem. (1998) 70(6):2357-2368.
141. HE J, CHENY, FARZAN M et al.: CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature (1997) 385(6617):645-649.
142. MICHAEL NL, MOORE JP: HIV-1 entry inhibitors: evading the issue. Nat. Med. (1999) 5(7):740-742.
143. TAN J, TOWN T, MORI T et al.: CD45 opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/ 42 mitogen-activated protein kinase. J. Neurosci. (2000) 20(20):7587-7594.
144. HANISH UK, PRINZ M, ANGSTWURM K et al.: The protein tyrosine inhibitor AG126 prevents the massive microglial cytokine induction by pneumococcal cell walls. Eur. J. Immunol. (2001) 31(7):2104-2115.
145. ROSENSTIEL P, LUCIUS R. DEUSCHL G et al.: From theory to therapy: implications from an in vitro model of ramified microglia. Micr. Res. Tech. (2001) 54(1):18-25.
146. EL KHOURY J, HICKMAN SE, THOMAS CA et al.: Microglia, scavenger receptors, and the pathogenesis of Alzheimer's disease. Neurobiol. Aging (1998) 19(Suppl. 1):S81-84.
147. BRAZIL MI, CHUNG H, MAXFIELD FR: Effects of incorporation of immunoglobulin G and complement component C1q on uptake and degradation of Alzheimer's disease 1myloid fibrils by microglia. J. Biol. Chem. (2000) 275(22):16941-16947.
148. WEBSTER SD, YANG AJ, MARGOL L et al.: Complement component C1q modulates the phagocytosis of A beta by microglia. Exp. Neurol. (2000) 161(1):127-138.
149. WEBSTER SD, PARK M, FONSECA MI et al.: Structural and functional evidence for microglial expression of C1qR(p), the C1q receptor that enhances phagocytosis. J. Leukocyte Biol. (2000) 67(1):109-116.
150. KAKIMURA J, KITAMURA Y, TANIGUCHIT et al.: Bip/GRP-induced production of cytokines and uptake of amyloid-beta (1-42) peptide in microglia. Biochem. Biophys. Res. Commun. (2001) 281(1):6-10.
151. HALLIDAY G, ROBINSON SR, SHEPHERD C et al.: Alzheimer's disease and inflammation: a review of cellular and therapeutic mechanisms. Clin. Exp. Pharmacol. Physiol. (2000) 27(1-2):1-8.
152. RODRIGUEZ E, MÉNDEZ-ARMENTA M, VILLEDA-HERNÁNDEZ J et al.: Dapsone prevents morphological lesions and lipid peroxidation induced by quinolinic acid in rat corpus striatum. Toxicology (1999) 139(1-2):111-118.
153. RINGHEIM GE: Glial modulating and neurotrophic properties of propentofylline and its application to Alzheimer's disease and vascular dementia. Ann. N.Y. Acad. Sci. (2000) 903:529-534.
154. SCHUBERT P, MORINO T, MIAYAZAKI H et al.: Cascading glia reactions: a common pathomechanism and its differentiated control by cyclic nucleotide signaling. Ann. N.Y. Acad. Sci. (2000) 903:24-33.
155. PLASCHKE K, GRANT M, WEIGAND MA et al.: Neuromodulatory effect of propentofylline on rat brain under acute and long-term hypoperfusion. Br. J. Pharmacol. (2001) 133(1):107-116.
156. KITTNER B: Clinical trials of propentyfylline in vascular dementia. European/Canadian propentofylline study group. Alzheimer Dis. Assoc. Disord. (1999) 13(Suppl.3):S166-S171.
157. BATH PM, BATH FJ, ASPLUND K: Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke. Cochrance Database Syst. Rev. (2000) (2): CD000162.
158. SWEITZER SM, SCHUBERT P, DELEO JA: Propentofylline, a glial modulating agets, exhibits antiallodynic properties in a rat model of neuropathic pain. J. Pharmacol. Exp. Ther. (2001) 297(3):1210-1217.
159. SCHIFITTO G, SACKTOR N, MARDER K et al.: Randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment. Neurological AIDS Research Consortium. Neurology (1998) 53(2):391-396.
160. CHAO CC, HU S. PETERSON PK: Modulation of human microglial cell superoxide production by cyrokines. J. Leukocyte Biol. (1995) 58(1):65-70.
161. KITAMURA Y, TANIGUCHI T, KIMURA H et al.: Interleukin-4-inhibited mRNA expression in mixed rat glial and in isolated microglial cultures. J. Neuroimmunol. (2000) 106(1-2):95-104.
162. LODGE PA, SRIRAM S: Regulation of microglial activation by TGF-beta, IL-10, and CSF-1. J. Leukocyte Biol. (1996) 60(4):502-508.
163. HU S, CHAO CC, EHRELINCH LC et al.: Inhibition of microglial cell RANTES production by IL-10 and TGF-β. J. Leukocyte Biol. (1999) 65(6):815-821.
164. SAWADA M, SUZUMURA A, HOSOYA H et al.: Interleukin-10 inhibits both production of cytokines and expression of cytokine receptors in microglia. J. Neurochem. (1999) 72(4):1466-1471.
165. FLANDERS KC, REN RF, LIPPA CF: Transforming growth factor-betas in neurodegenerative diseases. Prog. Neurobiol. (1998) 54(1):71-85.
166. WYSS-CORAY T, LIN C, YAN F et al.: TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice. Nat. Med. (2001) 7(5):612-618.
167. BERNARDO A, LEVI G, MINGHETTI L: Role of the peroxisome proliferaror-activated receptorgamma (PPAR-gamma) and its natural ligand 15-deoxy-Delta12,14-prostaglandin J2 in the regulation of microglial functions. Eur. J. Neurosci. (2000) 12(7):2215-2223.
168. COMBS CK, JOHNSON DE, KARLO JC et al.: Inflammatory mechanisms in Alzheimer's disease: inhibition of β-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARγ agonists. J. Neurosci. (2000) 20(2):558-567.
169. KITAMURA Y, KAKIMURA J, MATSUOKA Y et al.: Activators of peroxisome proliferator-activated receptor-gamma (PPARgamma) inhibit indubible nitric oxide synthase expression but increase heme oxygenasc-1 expression in rat glial cells. Neurosci. Lett. (1999) 262(2):129-132.
170. SCHWARZ SC, SCHWARZ J, SAUTTER J et al.: Effects of macrophage migration inhibitory factor and macrophage migration stimulatory factor on function and survival of foetal dopaminergic grafts in the 6-hydroxydopamine rat model of Parkinsons disease. Exp. Brain Res. (1998) 120(1):95-103.
171. DELGADO R, CARLIN A, AIRAGHI L et al.: Melanocortin peptides inhibit production of proinflammatory cytokines and nitric oxide by activated microglia. J. Leukocyte Biol. (1998) 63(6):740-745.
172. VEGETO E, BONINCONTRO C, POLLIO G et al.: Estrogen prevents the lipopolysaccharide-induced inflammatory response in microglia. J. Neurosci. (2001) 21(6):1809-1818.
173. BARGER SW, CHAVIS JA, DREW PD: Dehydroepiandrosterone inhibits microglial nitric oxide production in a stimulus-specific manner. J. Neurosci. Res. (2000) 62(4):503-509.
174. ISHII K, MUELHAUSER F, LIEBEL U et al.: Subacute NO generation induced by Alzheimer's beta-amyloid in the living brain: reversal by inhibition of the inducible NO synthase. FASEB J. (2000) 14(11):1485-1489.
175. TRAN MH, YAMADA K, OLARIU A et al.: Amyloid-beta-peptide induces nitric oxide production in rat hippocampus: association with cholinergic dysfunction and amelioration by inducible nitric oxide synthase inhibitor. FASEB J. (2001) 15(8):1407-1409.
176. FINE SM, MAGGIRWAR SB, ELLIOTT PR et al.: Proteasome blocker inhibit TNF-alpha release by lipopolysaccharide stimulated macrophages and microglia: implications for HFV-1 dementia. J. Neuroimmunol. (1999) 95(1):55-64.
177. MAYNE M, NI W, YAN HJ et al.: Antisense oligonucleotide inhibition of tumor necrosis factor-alpha expression is neuroprotective after intracerebral hemorrhage. Stroke (2001) 32(1): 240-247.
178. TERRADO J, MONNIER D, PERRELET D et al.: Soluble TNF receptors partially protect injured motoneurons in the postnatal CNS. Eur. J. Neurosci. (2000) 12(9):3443-3447.
179. PETERSON PK, HU S, SHENG WS et al.: Thalidomide inhibits tumor necrosis factor-alpha production by lipopolysaccharide- and liparabinomannan-stimulated human microglial cells. J. Infect. Dis. (1995) 172(4):1137-1140.
180. WILLARD LB, HAUSS-WEGRZYNIAK B, DANYSZ W et al.: The cytotoxicity of chronic neuroinflammation upon basal forebrain cholinergic neurons of rats can be attenuated by glutamatergic antagonism or cyclooxygenase-2 inhibition. Exp. Brain Res. (2000) 134(1):58-65.
181. YERMAKOVA A, O'BANION MK: Cyclooxygenases in the central nervous system: implications for treatment of neurological disorders. Curr. Pharm. Des. (2000) 6(17):1755-1760.
182. MCBRIDE CB, MCPHAIL LT, STEEVES JD: Emerging therapeutic targets in caspase-dependent disease. Emerg. Ther. Targets (1999) 3(3):391-411.
183. LU X, BING G, HAGGT: Naloxone prevents microglia-induced degeneration of dopaminergic substantia nigra neurons in adult rat. Neuroscience (2000) 97(2):285-291.
184. SUZUMURA A, SAWADA M: Effects of vesnarinone on cytokine production and activation of murine microglia. Life Sci. (1999) 64(14):1197-1203.
185. PERSIDSKY Y, LIMOGES J, RASMUSSEN J et al.: Reduction of glial immunity and neuropathology by a PAF antagonist and an MMP and TNFalpha inhibitor in SCID mice with HIV-1 encephalitis. J. Neuroimmunol. (2001) 114(1-2):57-68.
186. TIKKA TM, KOISTINAHO JE: Minocycline provides neuroprotection against a n-methyl-d-aspartate neurotoxicity by inhibiting microglia. J. Immunol. (2001) 166(12):7527-7533.
187. DAVOUST N, NATAF S, REIMAN R et al.: Central nervous system-targeted expression of the complement inhibitor sCrry prevents experimental allergic encephalomyelitis. J. Immunol. (1999) 163(12):8551-6656.
188. MORGAN BP, RUSHMERE NK, HARRIS CL: Therapeutic uses of recombinant complement receptors. Biochem. Soc. Trans. (1998) 26(1):49-54.
189. SAHUL A, LAMBRIS JD: Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics. Immunopharmacology (2000) 49(1-2):133-148.
190. DU ZY, LI XY: Effects of ginkgolides on interleukin-1, tumor necrosis factor-α and nitric oxide production by rat microglia stimulated with lipopolysaccharide in vitro. Arzneimittel-Forschung (1998) 48(12):1126-1130.
191. GONG YS, ZHANG JT: Effect of 17-beta-estradiol and ginsenoside Rg1 on reactive microglia induced by beta-amyloid peptides. J. Asian Nat. Prod. Res. (1999) 1(3):153-161.
192. DASCHIELL SM, RUS H, KOSKI CL: Terminal complement complexes concomitantly stimulate proliferation and rescue of Schwann cells from apoptosis. Glia (2000) 30(2):187-198.
193. DOUGHERTY KD, DREYFUS CF, BLACK IB: Brain-derived neurotrophic factor in astrocytes, oligodendrocytes and microglia/macrophages after spinal cord injury. Neurobiol. Dis. (2000) 7(6):574-585.
194. SATAKE K, MATSUYAMAY, KAMIYA M et al.: Up-regulation of glial cell line-derived neurotrophic factor (GDNF) following traumatic spinal cord injury. Neuroreport (2000) 11 (17):3877-3881.
195. ALDSKOGIUS H: Microglia in neuroregeneration. Micr. Res. Tech. (2001) 54(1):40-46.
196. HINKS GI, FRANKLIN RJM: Distinctive patterns of PDGF-A, FGF-2, IGF-1 and TGF-β1 gene expression during remyelingation of experimentally-induced spinal cord demyelination. Mol. Cell. Neurosci. (1999) 14(2):153-168.
197. MENTLEIN R, LUDWIG R, MARTENSEN I: Proteolytic degradation of Alzheimer's disease amyloid beta-peptide by a metalloproteinase from microglia cells. J. Neurochem. (1998) 70(2):721-726.
198. WATANABE H, ABE H, TAKEUCHIS et al.: Protective effect of microglial conditioning medium on neuronal damage induced by glutamate. Neurosci. Lett. (2000) 289(1):53-56.
199. ROSALES AA, ROQUE RS: Microglia-derived cytotoxic factors. Part I: inhibition of tumor cell growth in vitro. Brain Res. (1997) 748(1-2):195-204.
200. BAHR M, PRZYREMBEL C: Myelin from peripheral and central nervous system is a non-permissive substrate for retinal ganglion cell axons. Exp. Neurol. (1995) 134(1):87-93.
201. BANDTLOW CE, SCHWAB ME: NI-35/ 250/nogo-a: a neurite growth inhibitor restricting structural plasticity and regeneration of nerve fibers in the adult vertebrate CNS. Glia (2000) 29(2):175-181.
202. ROTSHENKERS: Co-operation between Schwann cells, fibroblasts and macrophages after axonal injury: a prelude for successful regeneration. In: Glial Interfaces in the Nervous System - Role in Repair and Plasticity. Aldskogius H, Fraher J(Eds.), IOS Press, Amsterdam, 2001. In press.
203. REICHERT F, ROTSHENKER S: Deficient activation of microglia during optic nerve degeneration. J. Neuroimmunol. (1996) 70(2):153-161.
204. LIU L, PERSSON JKE, SVENSSON M et al.: Glial cell responses, complement and clusterin in spinal cord dorsal horn, dorsal funiculus and gracile nucleus following dorsal root transect!on. Glia (1998) 23(3):221-238.
205. OUSMAN S, DAVIDS: MIP-1α, MCP-1, GM-CSF, and TNF-α control the immune cell response that mediates rapid phagocytosis of myelin from the adult mouse spinal cord. J. Neurosci. (2001) 21(13):4649-4656.
206. BRÜCK W: The role of macrophages in Wallerian degeneration. Brain Pathol. (1997) 7(2):741-752.
207. DAILEY AT, AVELLINO AM, BENTHEM L et al.: Complement depletion reduces macrophage infiltration and activation during Wallerian degeneration and axonal regeneration. J. Neurosci. (1998) 18(17):6713-6722.